Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients
Authors:
- Thierry BègeTBThierry Bège
- Bernard LelongBLBernard Lelong
- Frederic ViretFVFrederic Viret
- Olivier TurriniOTOlivier Turrini
- Jerome GuiramandJGJerome Guiramand
- Delphine TopartDTDelphine Topart
- Laurence Moureau-ZabottoLMLaurence Moureau-Zabotto
- Anthony GonçalvesAGAnthony Gonçalves
- Jean Robert DelperoJDJean Robert Delpero
- 21 January 2009
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (4) , 856-860
Abstract
Combining conventional systemic chemotherapy with the angiogenesis inhibitor bevacizumab is now recommended as a first treatment for metastatic colorectal neoplasms. The risk for short-term postoperative complications related to bevacizumab has been assessed. Late postoperative complications related to bevacizumab have also been suggested by preliminary reports. We reviewed a cohort of 142 patients with previous surgery for primary colonic or rectal tumor and without evidence of local recurrence, receiving bevacizumab for metastatic disease. Four patients experienced a late surgical site complication related to bevacizumab. Common features were rectal location, low anastomosis, and preoperative irradiation. Combining these three factors, the risk of a bevacizumab-related complication was 4 in 27 (14.8%); if previous history of postoperative leakage was reported, the risk was raised to 2 in 4. No complications occurred in colonic location or the non-irradiated patients. The mechanism of these complications could be ischemic lesion in post-irradiated tissues involving anastomoses. We conclude that angiogenesis inhibitors should be carefully considered for patients having low colorectal anastomosis and previous irradiation.Keywords
This publication has 11 references indexed in Scilit:
- “Spontaneous,” delayed colon and rectal anastomotic complications associated with bevacizumab therapyJournal of Surgical Oncology, 2007
- Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti–Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive TumorsCancer Research, 2007
- Delayed Rectovaginal Fistula: A Potential Complication of Bevacizumab (Avastin)Diseases of the Colon & Rectum, 2007
- Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancerGut, 2007
- High incidence of fistula formation during bevacizumab treatment in rectal cancer patientsActa Oncologica, 2007
- Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three casesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabJournal of Surgical Oncology, 2005
- Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of BevacizumabJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Radiation-induced hypoxia may perpetuate late normal tissue injuryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001